← Back to Analyst Consensus 
ACAD Buy
ACADIA PHARMACEUTICALS INC
Current Price —
Implied Upside —
Analysts 26
30-Day Momentum
▲ 0 upgrades / ▼ 1 downgrades / 2 reiterations from 3 firms
Next Earnings
Nov 4, 2026 (9 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 19, 2026 | Needham | reiterate | Buy → Buy | — | 50% |
| Oct 13, 2026 | UBS | downgrade | Buy → Neutral | — | 54% |
| Oct 8, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| Sep 25, 2026 | Deutsche Bank | maintain | Buy → Buy | — | 57% |
| Sep 25, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Sep 25, 2026 | Citizens | maintain | Market Outperform → Market Outperform | — | 47% |
| Sep 25, 2026 | BMO Capital | maintain | Outperform → Outperform | — | 53% |
| Sep 25, 2026 | Needham | maintain | Buy → Buy | — | 50% |
| Sep 24, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| Sep 24, 2026 | Needham | reiterate | Buy → Buy | — | 50% |
| Aug 25, 2026 | Deutsche Bank | maintain | Buy → Buy | — | 57% |
| Aug 25, 2026 | Morgan Stanley | maintain | Equal-Weight → Equal-Weight | — | 54% |
| Aug 25, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| Aug 17, 2026 | UBS | maintain | Buy → Buy | — | 54% |
| Aug 12, 2026 | Needham | maintain | Buy → Buy | — | 50% |
| Aug 10, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| Aug 5, 2026 | Oppenheimer | maintain | Perform → Perform | — | 52% |
| Aug 5, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| Aug 5, 2026 | Citizens | maintain | Market Outperform → Market Outperform | — | 47% |
| Jul 21, 2026 | BMO Capital | maintain | Outperform → Outperform | — | 53% |
| Jul 21, 2026 | Stifel | maintain | Hold → Hold | — | 53% |
| Jul 7, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| Jun 30, 2026 | B of A Securities | maintain | Buy → Buy | — | 53% |
| Jun 29, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| Jun 29, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| May 8, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| May 7, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| Mar 25, 2026 | B of A Securities | upgrade | Neutral → Buy | — | 53% |
| Mar 4, 2026 | JP Morgan | maintain | Overweight → Overweight | — | 54% |
| Feb 27, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| Feb 26, 2026 | TD Cowen | maintain | Buy → Buy | $37 | 54% |
| Feb 26, 2026 | RBC Capital | maintain | Outperform → Outperform | $30 | 55% |
| Feb 26, 2026 | Citizens | maintain | Market Outperform → Market Outperform | $35 | 47% |
| Feb 26, 2026 | Stifel | maintain | Hold → Hold | $24 | 53% |
| Feb 24, 2026 | Wolfe Research | initiate | — → Outperform | $33 | 53% |
| Feb 23, 2026 | Mizuho | upgrade | Neutral → Outperform | $35 | 52% |
| Feb 6, 2026 | Oppenheimer | maintain | Perform → Perform | $23 | 52% |
| Feb 3, 2026 | RBC Capital | maintain | Outperform → Outperform | $31 | 55% |
| Feb 3, 2026 | Citizens | reiterate | Market Outperform → Market Outperform | $34 | 47% |
| Feb 3, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | $37 | 44% |
| Jan 6, 2026 | Citigroup | maintain | Buy → Buy | $36 | 54% |
| Jan 6, 2026 | UBS | maintain | Buy → Buy | $40 | 54% |
| Dec 15, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $37 | 44% |
| Dec 11, 2025 | Stifel | maintain | Hold → Hold | $25 | 53% |
| Dec 2, 2025 | Mizuho | maintain | Neutral → Neutral | $29 | 52% |
| Nov 17, 2025 | JP Morgan | maintain | Overweight → Overweight | $31 | 54% |
| Nov 6, 2025 | RBC Capital | maintain | Outperform → Outperform | $32 | 55% |
| Nov 6, 2025 | Needham | maintain | Buy → Buy | $29 | 50% |
| Oct 21, 2025 | Citigroup | initiate | — → Buy | $33 | 54% |
| Sep 29, 2025 | JP Morgan | maintain | Overweight → Overweight | $33 | 54% |
Price Target Trend
Jun 11, 2026 Oct 26, 2026
EPS Estimates
0q —
+1y —
+1q —
0y —
Cross-Platform Signals
No cross-platform signals in the last 90 days